geoffrey modest medical blogs

as a reference to the Lp(a) studies in the pipeline, one of which involved direct PCSK9 effects: enclisiran (which is also spelled inclisiran in the NJM study...), which the FDA unexpectedly (by me) approved without documentation of clinical benefit: https://gmodestmedblogs.blogspot.com/2025/11/oral-pcsk9-improves-all-bad-lipids.html  - -- as a summary of what I have found of several of these Lp(a) inhibitors:     -- muvalapin (oral small-molecule): 63-65% reduction in Lp(a), with benefit within 4 weeks: https://jamanetwork.com/journals/jama/fullarticle/2808864       -- pelacarsen (antisense oligonucleotide that targets the Lp(a) gene): up to 80% reduction in Lp(a):   https://www.sciencedirect.com/science/article/pii/S1933287425003228     -- evinacumab (anti-ANGPTL3 mAb): 16.5% reduction in Lp(a): https://www.sciencedirect.com/science/article/pii/S1933287425003228     -- lomitapide (microsomal triglyceride transf...

  A secondary analysis of the ASPREE study found an increase in anemia in the elderly taking  low-dose aspirin (see  aspirin inc anemia AnnIntMed2023  in dropbox or  doi:10.7326/M23-0675 ).    Details : -- 18,153 persons were randomly assigned to 100 mg of aspirin daily or placebo in the ASPirin in Reducing Events in the Elderly (ASPREE) trial of community-dwelling persons at least 70 years old, or Black or Hispanic persons at least 65 years old, in Australia and the US, with enrollment from 2010 to 2015 -- mean age 74, 56% female, 87% were white from Australia, 6% were white from the US, 3.9% Black ,  2.5% Hispanic -- all were community-based: 32% lived at home alone, 68% with others -- smoking status was never in 55%/former in 41%/current in 4%; cancer history 19%; BMI 24% normal/29% obese/45% overweight; waist circumference high in 45% -- mean baseline hemoglobin 14.2 g/dL -- mean blood pressure 139/77, eGFR 74, CKD 29%, hypertension 74%, ...